MEDIVIR, INTERIM REPORT, 1 January - 30 September 2004

MEDIVIR, INTERIM REPORT, 1 January - 30 September 2004 · Medivir's major and rapid advances within hepatitis C research have resulted in one protease project reaching its preclinical optimization phase. · In August, Medivir and Novartis resolved the partly overlapping patent issue on ME-609 (herpes) in the US. · The collaboration between Medivir and Biovitrum in the diabetes segment, which began in July, is now fully up and running. · Medivir's new rights issue was fully subscribed in June, raising the company SEK 322.5 m before deducting issue costs. · Net sales amounted to SEK 18.4 m in the period (148.2 inc. CCS, 63.1 exc. CCS). · The loss after tax was SEK -131.6 m (previous year: a profit of SEK 2.3 m for the group included gains from the divestiture of CCS, and SEK -0.9 m for the research operations also included these gains). Earnings per share were SEK -12.25 (0.27). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Financial Statement will be published on 18 February 2005 The Three-month Interim Report will be published on 21 April 2005 The Annual General Meeting will be held on 21 April 2005, from 3 p.m. Medivir's financial reports are available from its Website, from these dates, under the 'Financial Information' heading. The Medivir Group Medivir is an innovative, specialist research corporation that develops drugs with the objective of becoming a sustaining and profitable pharmaceuticals corporation. Medivir is located in Huddinge, Sweden and near Cambridge, UK. Medivir's research is oriented on developing new drug compounds based on polymerases and proteases as target enzymes. The group consists of Medivir AB, its subsidiary Medivir UK Ltd. and Medivir Personal AB. As of 30 September 2004, the group had 125 employees. Medivir was listed on the Stockholm Exchange O-list in 1996. Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has five projects in clinical development phases, each with a unique clinical profile. The company's broad-based preclinical research portfolio houses six defined projects and nearly ten activities in various preclinical phases. Medivir AB (publ), Lunastigen 7, SE-141 44 Huddinge, Sweden, tel (switchboard): +46 (0)8 546 83100 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


Documents & Links